and does not reflect the company position". The statement says GSK has acted responsibly: "All paediatric studies have been made available to the FDA and regulatory agencies worldwide." Spokeswoman Mary Anne Rhyne added: "Data from paediatric studies of Paxil have been communicated publicly in more than two dozen presentations at major medical meetings." Paxil has been approved by the FDA for use in adults with depression -but not children and adolescents. In Britain the drug is marketed as Seroxat, and in June 2003 the Department of Health, concerned about suicide risks, prohibited doctors from prescribing it to children under 18. The same month,the FDA recommended that it should not be prescribed to depressed young people.
However, if a drug has been approved for one condition, American doctors may then prescribe it for any complaint in any patient; this is called "off-label" use. Federal law does not require companies to make any studies of such off-label uses available to doctors. Spitzer's office instead charges GSK with consumer fraud, under state law.
Some doctors contend that the issue that really needs to be addressed is that neither the companies nor the regulator have a well defined responsibility to publicize negative results."It's perhaps too common for negative trials not to be submitted for publication,"says Wayne Goodman, a professor of psychiatry at the University of Florida who sits on the FDA panel that evaluates psychiatric drugs."That's not necessarily a problem if a drug is not going to make it to market. But if it is a marketed compound as in this case, then I think clinicians need access to all the available data." David Fassler, a psychiatrist specializing in paediatric depression at the University of Vermont, adds:"If 20 studies are done, one is likely to show significance by chance. If that's the only one that gets published, and I don't know that there were 19 other studies with different results, it really skews the perception and ultimately alters clinical care."
The GSK lawsuit opens a new front in a wider war that Spitzer has declared against corporate targets. The 44-year-old Harvard Law School graduate, who became attorneygeneral in 1999, is widely believed to be preparing to campaign for governor of New York,and the cases he has launched have generated nationwide publicity.Spitzer has gone after the mutual fund industry, polluting power plants and the former New York Stock Exchange chairman Dick Grasso, whose "excessive" $188-million compensation package Spitzer is challenging. And the current lawsuit may not be the last time the drug companies hear from Spitzer's office. "It's certainly an issue that is not going to end with this case,"says Conway.
